8-K: Karyopharm Unveils 2025 Revenue, Eyes Transformative 2026

Karyopharm Therapeutics announced preliminary unaudited 2025 revenue and cash figures, while highlighting key clinical trial milestones expected in 2026 for myelofibrosis and endometrial cancer.

Summary

• Preliminary unaudited total revenue for the fourth quarter ended December 31, 2025, is approximately $33 million.
• Preliminary unaudited total revenue for the full year ended December 31, 2025, is approximately $145 million.
• Preliminary unaudited U.S. XPOVIO net product revenue for the fourth quarter ended December 31, 2025, is approximately $32 million.
• Preliminary unaudited U.S. XPOVIO net product revenue for the full year ended December 31, 2025, is approximately $115 million.
• Cash, cash equivalents, restricted cash, and investments as of December 31, 2025, were approximately $64 million.
• Existing liquidity, including expected revenue from XPOVIO sales and license agreements, is projected to fund planned operations into the second quarter of 2026.
• Top-line data from the Phase 3 SENTRY trial in myelofibrosis is on track for March 2026.
• Top-line data from the Phase 3 XPORT-EC-042 trial in endometrial cancer is on track for mid-2026.
• Demand for XPOVIO in multiple myeloma was consistent in 2025 compared to 2024, with global patient access expanding to over 50 countries.
• Enrollment for the Phase 3 SENTRY trial was completed in early September 2025 with 353 patients.
• Preliminary blinded aggregate safety data from the first 61 patients in the SENTRY trial with over 12 months follow-up may suggest improvements in adverse events compared to previous data.

Sentiment

Score: 6

Explanation: The filing presents a mixed but generally positive outlook, driven by consistent product demand and upcoming significant clinical trial readouts. However, the short cash runway and competitive market introduce notable financial and operational risks.

Positives

• Demand for XPOVIO in the multiple myeloma market remained consistent in 2025 compared to 2024.
• Global patient access for selinexor expanded in 2025, with favorable reimbursement decisions in Spain and China, and additional regulatory approvals in over 50 countries.
• Completed enrollment of the Phase 3 SENTRY trial in myelofibrosis with 353 patients, a significant milestone.
• Preliminary blinded aggregate safety data from the SENTRY trial suggests potential improvements in both hematologic and non-hematologic treatment emergent adverse events.
• Data from the Phase 2 XPORT-MF-035 trial suggests potential for single-agent clinical activity of selinexor in heavily pretreated myelofibrosis patients.
• Strategic financing transactions were completed, extending the cash runway beyond the expected top-line readout of the Phase 3 SENTRY trial.
• The company anticipates 2026 to be a catalyst-rich and potentially transformative year with two high-potential Phase 3 data readouts.

Negatives

• The preliminary unaudited financial figures are subject to completion of customary annual review and audit procedures.
• The multiple myeloma marketplace is increasingly competitive.
• Cash, cash equivalents, restricted cash, and investments of approximately $64 million are expected to fund operations only into the second quarter of 2026, indicating a short liquidity runway.
• The company cautions that preliminary baseline characteristics and preliminary blinded aggregate safety data from the Phase 3 SENTRY trial may not ultimately be reflective of the actual trial results.

Risks

• There is no guarantee that Karyopharm will successfully commercialize XPOVIO.
• There is no guarantee that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development will continue.
• There is no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation.
• Risks exist regarding the adoption of XPOVIO in the commercial marketplace.
• The timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval are uncertain.
• The ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval is a risk.
• Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials, are subject to uncertainty.
• The content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites, and publication review bodies, including with respect to the need for additional clinical trials, pose risks.
• The ability of Karyopharm or its third-party collaborators or successors in interest to fully perform their respective obligations under applicable agreements is a risk.
• Karyopharm's ability to enroll patients in its clinical trials is a factor of uncertainty.
• Unplanned cash requirements and expenditures could impact financial stability.
• Substantial doubt exists regarding Karyopharm's ability to continue as a going concern.
• Development or regulatory approval of drug candidates by Karyopharm's competitors for products or product candidates in which Karyopharm is currently commercializing or developing presents a competitive risk.
• Karyopharm's ability to obtain, maintain, and enforce patent and other intellectual property protection for any of its products or product candidates is a risk.

Future Outlook

Karyopharm anticipates 2026 to be a transformative year, driven by two high-potential Phase 3 data readouts: the SENTRY trial in myelofibrosis in March 2026 and the XPORT-EC-042 trial in endometrial cancer in mid-2026. The company expects its existing liquidity to fund operations into the second quarter of 2026 and plans to maintain its commercial foundation for XPOVIO in the competitive multiple myeloma market while supporting global launches by its partners.

Management Comments

• "2026 has the promise to be a transformative year for Karyopharm and the patient communities that we intend to serve, with top-line data from our Phase 3 SENTRY trial in myelofibrosis expected in March." Richard Paulson, President and Chief Executive Officer.
• "Positive data from our SENTRY trial could unlock our opportunity to improve patient outcomes and redefine the standard-of-care in myelofibrosis." Richard Paulson, President and Chief Executive Officer.
• "Our teams are actively preparing for regulatory filings, commercialization and the opportunity to rapidly launch with the first ever combination therapy in a multi-billion dollar market." Richard Paulson, President and Chief Executive Officer.
• "With two high-potential data readouts this year, 2026 is expected to be a catalyst-rich year that could position us for tremendous long-term value creation." Richard Paulson, President and Chief Executive Officer.

Industry Context

Karyopharm operates in highly competitive oncology markets, particularly in multiple myeloma, where XPOVIO has maintained consistent demand. The company is addressing significant unmet needs in myelofibrosis, where current JAK inhibitors like ruxolitinib have limitations, especially concerning anemia, and in endometrial cancer, specifically for TP53 wild-type pMMR patients who show less benefit from immune checkpoint inhibitors. The strategic focus on combination therapy in myelofibrosis and biomarker-driven patient populations in endometrial cancer aligns with broader trends in precision oncology.

Comparison to Industry Standards

• The Phase 3 SENTRY trial evaluates selinexor in combination with ruxolitinib, which is the most commonly prescribed JAK inhibitor for myelofibrosis, directly comparing to the existing standard of care.
• Preliminary blinded aggregate safety data from the SENTRY trial may suggest improvements in both hematologic and non-hematologic treatment emergent adverse events compared to Phase 1 data evaluating selinexor with ruxolitinib and historical ruxolitinib monotherapy data.
• The Phase 3 XPORT-EC-042 trial targets TP53 wild-type pMMR tumors in endometrial cancer, an area with an unmet need where immune checkpoint inhibitors have shown less benefit compared to dMMR tumors, positioning selinexor to address a specific patient population.

Stakeholder Impact

• Shareholders face potential for significant value creation if upcoming clinical trials yield positive results, but also bear risks associated with the short cash runway and competitive market dynamics.
• Patients with myelofibrosis and endometrial cancer could benefit from new treatment options if selinexor's clinical trials are successful, potentially improving outcomes.
• Employees will continue to focus on advancing clinical development programs and commercialization efforts for XPOVIO.
• Partners involved in global launches of selinexor stand to benefit from continued support and potential expansion into new indications following regulatory approvals.

Next Steps

• Report top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026.
• Prepare for regulatory filings and commercialization for selinexor in myelofibrosis if SENTRY data is positive.
• Report top-line data from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.
• Report top-line data from all patients in the 60 mg cohort of the Phase 2 SENTRY-2 trial with at least 24 weeks of follow-up in the second half of 2026.
• Maintain the commercial foundation and drive increased XPOVIO revenues in the multiple myeloma marketplace.
• Continue to support global launches by partners following regulatory and reimbursement approvals for selinexor in ex-U.S. territories.
• Report top-line data from the Phase 3 XPORT-MM-031 (EMN29) trial in the second half of 2026.
• Continue to enroll patients into the XPORT-EC-042 trial of selinexor as a maintenance monotherapy for patients with TP53 wild-type advanced or recurrent endometrial cancer.

Key Dates

Recommendation

The company has a short cash runway, expected to last only into Q2 2026, which is a significant financial concern. While preliminary 2025 financial results show consistent XPOVIO demand and global expansion, the revenue figures do not indicate strong growth. The upcoming Phase 3 data readouts in myelofibrosis (March 2026) and endometrial cancer (mid-2026) are major catalysts that could be transformative for the company's valuation. However, the outcome of these trials is uncertain, and the explicit mention of "substantial doubt exists regarding Karyopharm's ability to continue as a going concern" highlights the high risk. An investor should hold to await the results of these critical trials, as positive data could significantly de-risk the investment and lead to substantial upside, while negative data could severely impact the company's viability. The current position is highly speculative, balancing near-term financial constraints with high-impact clinical potential.

Keywords

Karyopharm, KPTI, XPOVIO, selinexor, myelofibrosis, endometrial cancer, multiple myeloma, SENTRY trial, XPORT-EC-042, oncology, cancer therapy, pharmaceutical, clinical trial, revenue, cash, financial results, biotech, drug development